So many things not to worry about or notice … https://t.co/huAIv5bxLq pic.twitter.com/MqE1p2oXTI
— Jennifer Margulis (@JenniferMarguli) January 3, 2022
An 84-year-old Japanese woman presented to our
department with a three-day history of genital necrosis. She had received her
first dose of Pfizer–BioNTech (New York, NY, USA; Mainz, Germany) BNT162b2 mRNA
COVID-19 vaccine 26 days before admission. Nine days after the vaccination, she
developed increasing pain in her genital region. She denied any trauma or
precipitating event. Her medical history was significant for deep vein
thrombosis after orthopaedic surgery, for which she had been receiving edoxaban
over the past three years. She had no other risk factors for thrombosis.
Treatment was started with
ampicillin/sulbactam along with local wound care. Her fever, leukocytosis and
genital pain resolved within the first week. The skin lesions also improved:
more than 80% of the eschar had fallen off when she was discharged after one
month of admission (Fig. 2a),
and epithelization was almost completed another month later (Fig. 2b).
No comments:
Post a Comment